DOCSLIB.ORG

Localized Scleroderma Is Indeed LOCALIZED Skin, but May Involve Various Joints, Such As the Such As Thickening of the Skin on All the Fingers Possible

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Localized Scleroderma Is Indeed LOCALIZED Skin, but May Involve Various Joints, Such As the Such As Thickening of the Skin on All the Fingers Possible (arthralgia) during the course of their disease. The It’s important to look for physical signs of the or functional deformity. However, stabilization Our Three-Fold Mission Is pain is not limited to joints beneath the involved internal type of scleroderma (systemic sclerosis), (inactive disease) of localized scleroderma is indeed LOCALIZED skin, but may involve various joints, such as the such as thickening of the skin on all the fingers possible. The outlook and prognosis of localized Support, Education and knees, wrists and even the spine. (sclerodactyly), and thickening of the skin on the scleroderma is generally quite favorable. First, the Research SCLERODERMA Occasionally, this complication occurs before the face (without color changes). There are other clues disease is not fatal, does not appear to decrease appearance of lesions in the skin, causing some that can be identified during the initial examination. lifespan and, except for extremely rare situations, is confusion with rheumatoid arthritis for a short For example, patients with localized scleroderma not associated with another disease that has internal period of time. Eventually, the joint pains subside, do not have the typical changes at the base of the organ involvement. Secondly, in most instances even in the face of new skin involvement but an fingernails that are common in the internal (systemic the condition is self-limited, and this definitely association with spine arthritis has been reported. sclerosis) disease: tiny blood vessel changes that applies to individual areas of morphea. In those Along the same lines, it is highly unlikely that require a special magnifying lens for proper cases, no treatment is required or advisable, except patients with localized scleroderma progress and detection. Another important question is whether for some emollients or, in some cases, mild topical develop severe systemic (internal) conditions such patients have what is called Raynaud’s phenomenon. steroids. Therefore, systemic treatment with a as rheumatoid arthritis, or lupus erythematosus, This refers to the inability of the patient’s hands to medication or other treatment interventions (for or systemic sclerosis (the internal form of withstand cold exposure, so that the fingers may be example, ultraviolet light), are reserved for more scleroderma). Still, it is important to recognize that come pale, or even experience numbness and pain, extensive forms of localized scleroderma. There morphea and other types of localized scleroderma and/or develop a temporary bluish appearance with are many publications that reference favorable may be present in several of these systemic even mild cold temperatures, or when touching results when using certain medications, but these conditions, including systemic lupus erythematosus, a cold beverage, or getting some item from the have truly not been proven to work. Examples of systemic sclerosis, and blistering diseases. An freezer. Patients with localized scleroderma these medications include: phenytoin (Dilantin), association has been found with a parasitic disease generally do not have Raynaud’s phenomenon, systemic corticosteroids (cortisone), antimalarial (toxoplasma). While this does not imply that patients which is present in the majority of patients with drugs (plaquenil, chloroquine), cyclosporine, with localized scleroderma evolve to develop these systemic sclerosis. d-penicillamine, antibiotics (presumably to treat an conditions, it does emphasize the need for follow-up underlying Lyme disease problem.) and vitamin E. and periodic evaluations, especially in patients who Several blood tests may be performed, which, when A previously used vitamin D-based therapy (with continue to have active skin problems or develop abnormal, help to determine how active the disease calcitriol) has now been proven not to work. There new issues. is and how extensive or prolonged it may become. is some recent good news for patients with extensive These blood tests include the number of blood disease who require proven medicines and other Are There Any Tests to eosinophils (cell normally present in our blood), the interventions. Methotrexate (as an anti-inflammatory Prove the Diagnosis of level of blood immune proteins (immunoglobulins), drug) has proved effective in children with active and various blood auto-antibodies: antinuclear and extensive (and deep) morphea. It has some side Localized Scleroderma? antibodies (ANA), antibodies to single-stranded effects and should only be used when truly necessary. The diagnosis of localized scleroderma is mainly DNA (ssDNA) and antihistones antibodies. These Ultraviolet light (there are different forms of this by visual recognition, though a biopsy often may tests are not specific for localized scleroderma and therapy, depending on the light wavelength being be done to show increased collagen deposition and may be abnormal in other conditions, including used) has also shown considerable promise in patients Funding for this brochure was provided by an unrestricted other suggestive changes upon microscopic analysis the internal type of scleroderma. However, with active disease. In other situations or when educational grant from Actelion Pharmaceuticals USA, Inc. of the skin. The biopsy may also help determine specific antibodies that are common in systemic these treatments fail, there are other medicines that whether the disease is still active. However, skin sclerosis (typically anti-centromere antibodies or can be tried in spite of the fact that they have not lesions may extend even when the biopsy does not anti-topoisomerase or SCL70) are expected to be been proven to work yet in careful clinical research show any significant changes. The process of taking negative in patients with localized scleroderma. studies. There is definite agreement that physical a skin biopsy involves first numbing the skin with therapy to preserve full motion of the affected joints an injection containing a numbing medicine (for What Medicines Are is important. example, lidocaine), and then taking a small (3-4 May 2015 mm or about 0.15 inches) circular area of skin with Available? Please note that this brochure is provided for a special “punch biopsy” device. Generally, unless There is no absolute cure for localized scleroderma. educational purposed only. It is not intended to one is dealing with a much deeper involvement of An absolute cure could be defined as not only substitute for informed medical advice. the skin, larger biopsies are not necessary. Stitches complete stabilization of the skin lesions, but also are optional when the biopsy site is very small. Any disappearance of the changes that have taken place in The Scleroderma Foundation wishes to thank Vincent Falanga, biopsy will result in a small scar. the skin, under the skin, and any associated cosmetic M.D., Boston University, for his contribution to this brochure. Introduction be an autoimmune disease but, other than the presence a combination of different types of skin involvement. Prognosis: What Will generalized morphea. Extensive lesions of linear of blood autoantibodies (confusingly similar to those Patients with generalized morphea, because of the scleroderma, when cross joint lines, can impair Scleroderma means “hard skin.” The term “localized with some internal diseases), patients have no other extensive surface area involved, may encounter Happen? motion of that particular joint. Unless continued scleroderma” as a primary diagnosis refers to the fact known or profound defect in the immune system. considerable cosmetic disability resulting from the Morphea occurs in all age groups, and tends to be efforts are made to maintain a full range of motion Become a Member of the that this group of conditions is “localized” to the skin, appearance of the problem (many dark and light areas more common in women. to the affected joint with physical therapy, this Scleroderma Foundation with no internal organ involvement. Sometimes, of skin). Also, because of skin thickening over the Most patients develop only one or two patches of complication may be permanent and result in the When you become a the term “morphea” is used interchangeably with Types of Localized The Member Magazine of the Scleroderma Foundation joints, patients may have limited joint function. thickening that are frequently darker or lighter affected area (for example, the elbow, arm, finger, member of the localized scleroderma, creating some confusion. Scleroderma Scleroderma than the surrounding skin. A yellow discoloration etc.) being in a fixed position (contracture). Many Scleroderma Foundation, Morphea, in fact, is only one particular type of C) Linear Scleroderma – Linear scleroderma, patients with linear scleroderma, especially if older VOICE Names and terminology are widely varied and cause Rewind also may occur. The changes in skin color may last you support the localized scleroderma. It is important to understand as the name implies, shows a band or line of skin San Francisco a great deal of confusion in localized scleroderma. for years, in spite of improvement and softening at the age of onset of the disease, will have only organization’s mission of National Patient that localized scleroderma is different from the Patients are often told they have “scleroderma,” which thickening. It may extend deep into the skin and minor skin changes and minimal skin thickening. Education Conference even involve the underlying muscle. The band of skin of the skin. In general, morphea tends to involve
Load more

Recommended publications
  • Autoimmune Associations of Alopecia Areata in Pediatric Population - a Study in Tertiary Care Centre
    IP Indian Journal of Clinical and Experimental Dermatology 2020;6(1):41–44 Content available at: iponlinejournal.com IP Indian Journal of Clinical and Experimental Dermatology Journal homepage: www.innovativepublication.com Original Research Article Autoimmune associations of alopecia areata in pediatric population - A study in tertiary care centre Sagar Nawani1, Teki Satyasri1,*, G. Narasimharao Netha1, G Rammohan1, Bhumesh Kumar1 1Dept. of Dermatology, Venereology & Leprosy, Gandhi Medical College, Secunderabad, Telangana, India ARTICLEINFO ABSTRACT Article history: Alopecia areata (AA) is second most common disease leading to non scarring alopecia . It occurs in Received 21-01-2020 many patterns and can occur on any hair bearing site of the body. Many factors like family history, Accepted 24-02-2020 autoimmune conditions and environment play a major role in its etio-pathogenesis. Histopathology shows Available online 29-04-2020 bulbar lymphocytes surrounding either terminal hair or vellus hair resembling ”swarm of bees” appearance depending on chronicity of alopecia areata. Alopecia areata in children is frequently seen. Pediatric AA has been associated with atopy, thyroid abnormalities and a positive family history. We have done a study to Keywords: find out if there is any association between alopecia areata and other auto immune diseases in children. This Alopecia areata study is an observational study conducted in 100 children with AA to determine any associated autoimmune Auto immunity conditions in them. SALT score helps to assess severity of alopecia areata. Severity of alopecia areata was Pediatric population assessed by SALT score-1. S1- less than 25% of hairloss, 2. S2- 25-49% of hairloss, 3. 3.S3- 50-74% of hairloss.
    [Show full text]
  • Coexistence of Vulgar Psoriasis and Systemic Lupus Erythematosus - Case Report
    doi: http://dx.doi.org/10.11606/issn.1679-9836.v98i1p77-80 Rev Med (São Paulo). 2019 Jan-Feb;98(1):77-80. Coexistence of vulgar psoriasis and systemic lupus erythematosus - case report Coexistência de psoríase vulgar e lúpus eritematoso sistêmico: relato de caso Kaique Picoli Dadalto1, Lívia Grassi Guimarães2, Kayo Cezar Pessini Marchióri3 Dadalto KP, Guimarães LG, Marchióri KCP. Coexistence of vulgar psoriasis and systemic lupus erythematosus - case report / Coexistência de psoríase vulgar e lúpus eritematoso sistêmico: relato de caso. Rev Med (São Paulo). 2019 Jan-Feb;98(1):77-80. ABSTRACT: Psoriasis and Systemic lupus erythematosus (SLE) RESUMO: Psoríase e Lúpus eritematoso sistêmico (LES) são are autoimmune diseases caused by multifactorial etiology, with doenças autoimunes de etiologia multifatorial, com envolvimento involvement of genetic and non-genetic factors. The purpose de fatores genéticos e não genéticos. O objetivo deste relato of this case report is to clearly and succinctly present a rare de caso é expor de maneira clara e sucinta uma associação association of autoimmune pathologies, which, according to some rara de patologias autoimunes, que, de acordo com algumas similar clinical features (arthralgia and cutaneous lesions), may características clínicas semelhantes (artralgia e lesões cutâneas), interfere or delay the diagnosis of its coexistence. In addition, it podem dificultar ou postergar o diagnóstico de sua coexistência. is of paramount importance to the medical community to know about the treatment of this condition, since there is a possibility Além disso, é de suma importância à comunidade médica o of exacerbation or worsening of one or both diseases. The conhecimento a respeito do tratamento desta condição, já que combination of these diseases is very rare, so, the diagnosis existe a possibilidade de exacerbação ou piora de uma, ou de is difficult and the treatment even more delicate, due to the ambas as doenças.
    [Show full text]
  • Table of Contents (PDF)
    CJASNClinical Journal of the American Society of Nephrology October 2018 c Vol. 13 c No. 10 Editorials 1451 Metabolic Acidosis and Cardiovascular Disease Risk in CKD Matthew K. Abramowitz See related article on page 1463. 1453 Beware Intradialytic Hypotension: How Low Is Too Low? Jula K. Inrig See related article on page 1517. 1455 PD Solutions and Peritoneal Health Yeoungjee Cho and David W. Johnson See related article on page 1526. 1458 Proton Pump Inhibitors in Kidney Disease Benjamin Lazarus and Morgan E. Grams See related article on page 1534. 1460 Inching toward a Greater Understanding of Genetic Hypercalciuria: The Role of Claudins Ronak Jagdeep Shah and John C. Lieske See related article on page 1542. Original Articles Chronic Kidney Disease 1463 Effect of Treatment of Metabolic Acidosis on Vascular Endothelial Function in Patients with CKD: A Pilot Randomized Cross-Over Study Jessica Kendrick, Pratik Shah, Emily Andrews, Zhiying You, Kristen Nowak, Andreas Pasch, and Michel Chonchol See related editorial on page 1451. 1471 Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection Sara Yee Tartof, Jin-Wen Hsu, Rong Wei, Kevin B. Rubenstein, Haihong Hu, Jean Marie Arduino, Michael Horberg, Stephen F. Derose, Lei Qian, and Carla V. Rodriguez Clinical Nephrology 1479 Perfluorinated Chemicals as Emerging Environmental Threats to Kidney Health: A Scoping Review John W. Stanifer, Heather M. Stapleton, Tomokazu Souma, Ashley Wittmer, Xinlu Zhao, and L. Ebony Boulware Cystic Kidney Disease 1493 Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease Kristen L. Nowak, Wei Wang, Heather Farmer-Bailey, Berenice Gitomer, Mikaela Malaczewski, Jelena Klawitter, Anna Jovanovich, and Michel Chonchol Glomerular and Tubulointerstitial Diseases 1502 Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis Liliana Michelle Gomez Mendez, Matthew D.
    [Show full text]
  • Understanding and Managing Scleroderma
    Understanding and Managing Scleroderma A publication of Scleroderma Foundation 300 Rosewood Drive, Suite 105 Danvers, MA 01923 Maureen D. Mayes, M.D., M.P.H. Understanding and Understanding My notes and Managing Scleroderma Managing Scleroderma This booklet is intended to help people with scleroderma, their families and others interested ________________________ in learning more about the disease to better understand what scleroderma is, what effects ________________________ it may have, and what those with scleroderma can do to help themselves and their physicians ________________________ manage the disease. It answers some of the most frequently asked questions about ________________________ A publication of Maureen D. Mayes, M.D., M.P.H. Scleroderma Foundation 300 Rosewood Drive, Suite 105 scleroderma. Danvers, MA 01923 800-722-HOPE (4673) www.scleroderma.org www.facebook.com/sclerodermaUS www.twitter.com/scleroderma ________________________ Disclaimer The Scleroderma Foundation does not provide medical advice nor does it ________________________ endorse any drug or treatment mentioned herein. ________________________ The material contained in this booklet is presented for general information only. It is not intended to provide medical advice, to answer questions specific to the condition or problems of particular individuals, nor in ________________________ any way to substitute for the professional advice and care of qualified physicians. Mention of particular drugs and/or treatments is for ________________________ information purposes only and does not constitute an endorsement of said drugs and/or treatments. ________________________ Thanks! ________________________ The Scleroderma Foundation expresses its deep appreciation to the many ________________________ physicians whose efforts have led to this booklet. Special thanks are owed to Maureen D. Mayes, M.D., M.P.H., of the ________________________ University of Texas McGovern Medical School, Houston.
    [Show full text]
  • The Voice of the Patient
    The Voice of the Patient A series of reports from the U.S. Food and Drug Administration’s (FDA’s) Patient-Focused Drug Development Initiative Systemic Sclerosis Public Meeting: October 13, 2020 Report Date: June 30, 2021 Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration (FDA) 1 Table of Contents Introduction ............................................................................................................................ 3 Overview of Systemic Sclerosis ................................................................................................................. 3 Meeting Overview ..................................................................................................................................... 3 Report Overview and Key Themes ............................................................................................................ 5 Topic 1: Disease Symptoms and Daily Impacts That Matter Most to Patients .......................... 6 Perspectives on Most Significant Symptoms ............................................................................................ 6 Overall Impact of Systemic Sclerosis on Daily Life .................................................................................... 9 Topic 2: Patient Perspectives on Treatments for Systemic Sclerosis ....................................... 11 Perspectives on Current Treatments ...................................................................................................... 11 Perspectives on Ideal
    [Show full text]
  • Dermatological Findings in Common Rheumatologic Diseases in Children
    Available online at www.medicinescience.org Medicine Science ORIGINAL RESEARCH International Medical Journal Medicine Science 2019; ( ): Dermatological findings in common rheumatologic diseases in children 1Melike Kibar Ozturk ORCID:0000-0002-5757-8247 1Ilkin Zindanci ORCID:0000-0003-4354-9899 2Betul Sozeri ORCID:0000-0003-0358-6409 1Umraniye Training and Research Hospital, Department of Dermatology, Istanbul, Turkey. 2Umraniye Training and Research Hospital, Department of Child Rheumatology, Istanbul, Turkey Received 01 November 2018; Accepted 19 November 2018 Available online 21.01.2019 with doi:10.5455/medscience.2018.07.8966 Copyright © 2019 by authors and Medicine Science Publishing Inc. Abstract The aim of this study is to outline the common dermatological findings in pediatric rheumatologic diseases. A total of 45 patients, nineteen with juvenile idiopathic arthritis (JIA), eight with Familial Mediterranean Fever (FMF), six with scleroderma (SSc), seven with systemic lupus erythematosus (SLE), and five with dermatomyositis (DM) were included. Control group for JIA consisted of randomly chosen 19 healthy subjects of the same age and gender. The age, sex, duration of disease, site and type of lesions on skin, nails and scalp and systemic drug use were recorded. χ2 test was used. The most common skin findings in patients with psoriatic JIA were flexural psoriatic lesions, the most common nail findings were periungual desquamation and distal onycholysis, while the most common scalp findings were erythema and scaling. The most common skin finding in patients with oligoarthritis was photosensitivity, while the most common nail finding was periungual erythema, and the most common scalp findings were erythema and scaling. We saw urticarial rash, dermatographism, nail pitting and telogen effluvium in one patient with systemic arthritis; and photosensitivity, livedo reticularis and periungual erythema in another patient with RF-negative polyarthritis.
    [Show full text]
  • Visual Recognition of Autoimmune Connective Tissue Diseases
    Seeing the Signs: Visual Recognition of Autoimmune Connective Tissue Diseases Utah Association of Family Practitioners CME Meeting at Snowbird, UT 1:00-1:30 pm, Saturday, February 13, 2016 Snowbird/Alta Rick Sontheimer, M.D. Professor of Dermatology Univ. of Utah School of Medicine Potential Conflicts of Interest 2016 • Consultant • Paid speaker – Centocor (Remicade- – Winthrop (Sanofi) infliximab) • Plaquenil – Genentech (Raptiva- (hydroxychloroquine) efalizumab) – Amgen (etanercept-Enbrel) – Alexion (eculizumab) – Connetics/Stiefel – MediQuest • Royalties Therapeutics – Lippincott, – P&G (ChelaDerm) Williams – Celgene* & Wilkins* – Sanofi/Biogen* – Clearview Health* Partners • 3Gen – Research partner *Active within past 5 years Learning Objectives • Compare and contrast the presenting and Hallmark cutaneous manifestations of lupus erythematosus and dermatomyositis • Compare and contrast the presenting and Hallmark cutaneous manifestations of morphea and systemic sclerosis Distinguishing the Cutaneous Manifestations of LE and DM Skin involvement is 2nd most prevalent clinical manifestation of SLE and 2nd most common presenting clinical manifestation Comprehensive List of Skin Lesions Associated with LE LE-SPECIFIC LE-NONSPECIFIC Cutaneous vascular disease Acute Cutaneous LE Vasculitis Leukocytoclastic Localized ACLE Palpable purpura Urticarial vasculitis Generalized ACLE Periarteritis nodosa-like Ten-like ACLE Vasculopathy Dego's disease-like Subacute Cutaneous LE Atrophy blanche-like Periungual telangiectasia Annular Livedo reticularis
    [Show full text]
  • Interstitial Granuloma Annulare Triggered by Lyme Disease
    Volume 27 Number 5| May 2021 Dermatology Online Journal || Case Presentation 27(5):11 Interstitial granuloma annulare triggered by Lyme disease Jordan Hyde1 MD, Jose A Plaza1,2 MD, Jessica Kaffenberger1 MD Affiliations: 1Division of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA, 2Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA Corresponding Author: Jessica Kaffenberger MD, Division of Dermatology, The Ohio State University Medical Wexner Medical Center, Suite 240, 540 Officenter Place, Columbus, OH 43230, Tel: 614-293-1707, Email: [email protected] been associated with a variety of systemic diseases Abstract including diabetes mellitus, malignancy, thyroid Granuloma annulare is a non-infectious disease, dyslipidemia, and infection [3,4]. granulomatous skin condition with multiple different associations. We present a case of a man in his 60s There are multiple histological variants of GA, with a three-week history of progressive targetoid including interstitial GA. The histopathology of plaques on his arms, legs, and trunk. Skin biopsy classic GA demonstrates a focal degeneration of demonstrated interstitial granuloma annulare. collagen surrounded by an inflammatory infiltrate Additional testing revealed IgM antibodies to Borrelia composed of lymphocytes and histiocytes. In a less burgdorferi on western blot suggesting interstitial common variant, interstitial GA, scattered histiocytes granuloma annulare was precipitated by the recent are seen
    [Show full text]
  • ORIGINAL ARTICLE a Clinical and Histopathological Study of Lichenoid Eruption of Skin in Two Tertiary Care Hospitals of Dhaka
    ORIGINAL ARTICLE A Clinical and Histopathological study of Lichenoid Eruption of Skin in Two Tertiary Care Hospitals of Dhaka. Khaled A1, Banu SG 2, Kamal M 3, Manzoor J 4, Nasir TA 5 Introduction studies from other countries. Skin diseases manifested by lichenoid eruption, With this background, this present study was is common in our country. Patients usually undertaken to know the clinical and attend the skin disease clinic in advanced stage histopathological pattern of lichenoid eruption, of disease because of improper treatment due to age and sex distribution of the diseases and to difficulties in differentiation of myriads of well assess the clinical diagnostic accuracy by established diseases which present as lichenoid histopathology. eruption. When we call a clinical eruption lichenoid, we Materials and Method usually mean it resembles lichen planus1, the A total of 134 cases were included in this study prototype of this group of disease. The term and these cases were collected from lichenoid used clinically to describe a flat Bangabandhu Sheikh Mujib Medical University topped, shiny papular eruption resembling 2 (Jan 2003 to Feb 2005) and Apollo Hospitals lichen planus. Histopathologically these Dhaka (Oct 2006 to May 2008), both of these are diseases show lichenoid tissue reaction. The large tertiary care hospitals in Dhaka. Biopsy lichenoid tissue reaction is characterized by specimen from patients of all age group having epidermal basal cell damage that is intimately lichenoid eruption was included in this study. associated with massive infiltration of T cells in 3 Detailed clinical history including age, sex, upper dermis. distribution of lesions, presence of itching, The spectrum of clinical diseases related to exacerbating factors, drug history, family history lichenoid tissue reaction is wider and usually and any systemic manifestation were noted.
    [Show full text]
  • A Review of the Evidence for and Against a Role for Mast Cells in Cutaneous Scarring and Fibrosis
    International Journal of Molecular Sciences Review A Review of the Evidence for and against a Role for Mast Cells in Cutaneous Scarring and Fibrosis Traci A. Wilgus 1,*, Sara Ud-Din 2 and Ardeshir Bayat 2,3 1 Department of Pathology, Ohio State University, Columbus, OH 43210, USA 2 Centre for Dermatology Research, NIHR Manchester Biomedical Research Centre, Plastic and Reconstructive Surgery Research, University of Manchester, Manchester M13 9PT, UK; [email protected] (S.U.-D.); [email protected] (A.B.) 3 MRC-SA Wound Healing Unit, Division of Dermatology, University of Cape Town, Observatory, Cape Town 7945, South Africa * Correspondence: [email protected]; Tel.: +1-614-366-8526 Received: 1 October 2020; Accepted: 12 December 2020; Published: 18 December 2020 Abstract: Scars are generated in mature skin as a result of the normal repair process, but the replacement of normal tissue with scar tissue can lead to biomechanical and functional deficiencies in the skin as well as psychological and social issues for patients that negatively affect quality of life. Abnormal scars, such as hypertrophic scars and keloids, and cutaneous fibrosis that develops in diseases such as systemic sclerosis and graft-versus-host disease can be even more challenging for patients. There is a large body of literature suggesting that inflammation promotes the deposition of scar tissue by fibroblasts. Mast cells represent one inflammatory cell type in particular that has been implicated in skin scarring and fibrosis. Most published studies in this area support a pro-fibrotic role for mast cells in the skin, as many mast cell-derived mediators stimulate fibroblast activity and studies generally indicate higher numbers of mast cells and/or mast cell activation in scars and fibrotic skin.
    [Show full text]
  • 2017 Oregon Dental Conference® Course Handout
    2017 Oregon Dental Conference® Course Handout Nasser Said-Al-Naief, DDS, MS Course 8125: “The Mouth as The Body’s Mirror: Oral, Maxillofacial, and Head and Neck Manifestations of Systemic Disease” Thursday, April 6 2 pm - 3:30 pm 2/28/2017 The Mouth as The Body’s Mirror Oral Maxillofacial and Head and Neck Manifestation of Ulcerative Conditions of Allergic & Immunological Systemic Disease the Oro-Maxillofacial Diseases Region Nasser Said-Al-Naief, DDS, MS Professor & Chair, Oral Pathology and Radiology Director, OMFP Laboratory Oral manifestations of Office 503-494-8904// Direct: 503-494-0041 systemic diseases Oral Manifestations of Fax: 503-494-8905 Dermatological Diseases Cell: 1-205-215-5699 Common Oral [email protected] Conditions [email protected] OHSU School of Dentistry OHSU School of Medicine 2730 SW Moody Ave, CLSB 5N008 Portland, Oregon 97201 Recurrent aphthous stomatitis (RAS) Recurrent aphthous stomatitis (RAS) • Aphthous" comes from the Greek word "aphtha”- • Recurrence of one or more painful oral ulcers, in periods of days months. = ulcer • Usually begins in childhood or adolescence, • The most common oral mucosal disease in North • May decrease in frequency and severity by age America. (30+). • Affect 5% to 66% of the North American • Ulcers are confined to the lining (non-keratinized) population. mucosa: • * 60% of those affected are members of the • Buccal/labial mucosa, lateral/ventral tongue/floor of professional class. the mouth, soft palate/oropharyngeal mucosa • Etiopathogenesis: 1 2/28/2017 Etiology of RAU Recurrent Aphthous Stomatitis (RAS): Types: Minor; small size, shallow, regular, preceeded by prodrome, heal in 7-10 days Bacteria ( S.
    [Show full text]
  • Foot Pain in Scleroderma
    Foot Pain in Scleroderma Dr Begonya Alcacer-Pitarch LMBRU Postdoctoral Research Fellow 20th Anniversary Scleroderma Family Day 16th May 2015 Leeds Institute of Rheumatic and Musculoskeletal Medicine Presentation Content n Introduction n Different types of foot pain n Factors contributing to foot pain n Impact of foot pain on Quality of Life (QoL) Leeds Institute of Rheumatic and Musculoskeletal Medicine Scleroderma n Clinical features of scleroderma – Microvascular (small vessel) and macrovascular (large vessel) damage – Fibrosis of the skin and internal organs – Dysfunction of the immune system n Unknown aetiology n Female to male ratio 4.6 : 1 n The prevalence of SSc in the UK is 8.21 per 100 000 Leeds Institute of Rheumatic and Musculoskeletal Medicine Foot Involvement in SSc n Clinically 90% of SSc patients have foot involvement n It typically has a later involvement than hands n Foot involvement is less frequent than hand involvement, but is potentially disabling Leeds Institute of Rheumatic and Musculoskeletal Medicine Different Types of Foot Pain Leeds Institute of Rheumatic and Musculoskeletal Medicine Ischaemic Pain (vascular) Microvascular disease (small vessel) n Intermittent pain – Raynaud’s (spasm) • Cold • Throb • Numb • Tingle • Pain n Constant pain – Vessel center narrows • Distal pain (toes) • Gradually increasing pain • Intolerable pain when necrosis is present Leeds Institute of Rheumatic and Musculoskeletal Medicine Ischaemic Pain (vascular) Macrovascular disease (large vessels) n Intermittent and constant pain – Peripheral Arterial Disease • Intermittent claudication – Muscle pain (ache, cramp) during walking • Aching or burning pain • Night and rest pain • Cramps Leeds Institute of Rheumatic and Musculoskeletal Medicine Ulcer Pain n Ulcer development – Constant pain n Infected ulcer – Unexpected/ excess pain or tenderness Leeds Institute of Rheumatic and Musculoskeletal Medicine Neuropathic Pain n Nerve damage is not always obvious.
    [Show full text]